When does Opdivo (nivolumab) lose patent protection?
Opdivo is the branded form of nivolumab. Patent-expiration timing depends on which specific patent(s) and exclusivity components are being asked about (for example, drug patents vs. formulation/process patents vs. regulatory exclusivity). The most reliable way to check the exact “expire/exp” date for Opdivo is to look up the relevant patent family and its projected expiration dates.
DrugPatentWatch.com tracks these patent-expiration timelines for medicines and is a useful starting point for Opdivo: https://www.drugpatentwatch.com/p/ (search “Opdivo nivolumab” on the site).
What about Nulojix (belatacept) patent expiry?
Nulojix is the branded form of belatacept. Like Opdivo, the date people call “patent exp” can differ by patent family and by the type of exclusivity being referenced.
You can check the patent-expiration dates for Nulojix on DrugPatentWatch.com here (search “Nulojix belatacept” on the site): https://www.drugpatentwatch.com/p/
Are Opdivo and Nulojix related in patent timing?
No. Opdivo (nivolumab) and Nulojix (belatacept) are different drugs for different indications, so their patent families and expiration timelines are unrelated. Any “patent exp” you’re seeing for one will not predict the other.
If you meant “Opdivo + Nulojix” together as a comparison
People typically compare patent-expiry dates to estimate when lower-cost competition (including biosimilars, where applicable) might enter. But Opdivo is an antibody therapy (nivolumab), while Nulojix is a different antibody therapy class and product, so you’d still need to check each drug’s specific patent/exclusivity dates.
Can you share the exact line you saw (so I can match the right date)?
“Petent exp opdivo nuloyix” looks like a shorthand or a search query. If you paste the exact wording or the country (US vs EU vs UK) and whether you mean:
- “patent expiration” (a specific patent),
- “regulatory exclusivity”,
- or “biosimilar entry window,”
I can help you interpret what the date means and which exclusivity bucket it likely refers to.
Sources
- https://www.drugpatentwatch.com/p/